We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Adjuvant oral alkylating chemotherapy in patients with stage I epithelial ovarian cancer.
- Authors
Gallion, Holly H.; van Nagell, John R.; Donaldson, Elvis S.; Higgins, Robert V.; Powell, Deborah E.; Kryscio, Richard J.; Gallion, H H; van Nagell, J R; Donaldson, E S; Higgins, R V; Powell, D E; Kryscio, R J
- Abstract
From November 1973 to May 1986, 50 patients with Stage I epithelial ovarian cancer were treated at the University of Kentucky Medical Center (Lexington, KY) with oral Alkeran (melphalan) chemotherapy after primary surgery. Twenty-two patients had Grade 1 tumors, 23 patients had Grade 2 tumors, and five patients had Grade 3 tumors. Patients with ovarian tumors of borderline malignancy were excluded from this study. Twenty-eight patients received from six to 11 courses of chemotherapy and 22 patients completed 12 courses of chemotherapy. Chemotherapy was well tolerated and no patient died of chemotherapy-related complications. Thirty-eight patients underwent second-look laparotomy died of disease 41 months after diagnosis and one patient died with no evidence of disease 6 months after treatment. The actuarial survival of the total group of patients was 98% at 2 years and 94% at 5 years. Fewer than 12 months of chemotherapy may be necessary to obtain long-term survival in these patients.
- Subjects
ADENOCARCINOMA; ALKYLATING agents; CANCER relapse; COMBINED modality therapy; ORAL drug administration; OVARIAN tumors; REOPERATION; TUMOR classification; PARITY (Obstetrics)
- Publication
Cancer (0008543X), 1989, Vol 63, Issue 6, p1070
- ISSN
0008-543X
- Publication type
journal article
- DOI
10.1002/1097-0142(19890315)63:6<1070::AID-CNCR2820630605>3.0.CO;2-F